[Therapeutic usefulness of mepartricin in benign prostatic hypertrophy: 2 years' experience. Preliminary note on the effect of mepartricin on certain possible etiopathogenic factors in benign prostatic hypertrophy].Mirone, P Bocchini, A. Palmiéri et al.|PubMed|1988Cited by 0
[Mepartricin 150.000 (40 mg) vs mepartricin 50.000 U (13 mg) in the treatment of BIP. Double blind clinical trial].Vincenzo Mirone, T. Lotti, Domenico Prezioso et al.|PubMed|1996Cited by 0
Combinations in intracorporeal pharmacotherapy: Comparison between phentolamine and ketanserinA. Palmiéri, Vincenzo Mirone, Ciro Imbimbo et al.|Acta urologica italica|1992Cited by 0